Blood protein level predicts which breast cancer patients will survive radiotherapy

Researchers found that low levels of a protein called WRAP53 can predict whether breast cancer patients will benefit from radiation treatment and their risk of recurrence. The discovery, from a long-term Swedish trial, could help oncologists personalize treatment plans and identify patients needing alternative or additional therapies.

Originaltitel: Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial